00:00It's Benzinga, bringing Wall Street to Main Street.
00:03Kenview beat first quarter revenue and profit estimates as strong skin health and beauty sales
00:08boosted results while the company moves toward its planned $40 billion buyout by Kimberly Clark
00:13in the second half of the year, according to Reuters. The Tylenol maker reported first quarter
00:18adjusted earnings of $0.32 per share on $3.91 billion in revenue, surpassing Wall Street
00:25estimates of $0.26 per share and $3.84 billion in revenue. Net sales increased 4.5% year
00:33over year as skin health and beauty sales rose 8.4% to $1.06 billion, driven by higher global
00:41sales of brands, including Neutrogena and Aveeno. CEO Kirk Perry said the company remains focused
00:47on accelerating its business transformation plans. For all things money, visit Benzinga.com.
Comments